$BTAI
BioXcel Therapeutics, Inc.

2023 Q4 Form 10-Q Financial Statement

#000155837023018917 Filed on November 14, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $376.0K $341.0K
YoY Change 57.98% 148.91%
Cost Of Revenue $714.0K $512.0K
YoY Change 7833.33% 4554.55%
Gross Profit -$338.0K -$171.0K
YoY Change -247.6% -235.71%
Gross Profit Margin -89.89% -50.15%
Selling, General & Admin $9.603M $24.34M
YoY Change -53.53% 42.75%
% of Gross Profit
Research & Development $9.934M $19.62M
YoY Change -69.4% -11.07%
% of Gross Profit
Depreciation & Amortization $78.00K $79.00K
YoY Change -3.7% -7.06%
% of Gross Profit
Operating Expenses $19.54M $43.96M
YoY Change -63.22% 12.39%
Operating Profit -$19.88M -$48.30M
YoY Change -62.42% 23.87%
Interest Expense -$2.489M $3.252M
YoY Change 73.57% -12.11%
% of Operating Profit
Other Income/Expense, Net $108.0K -$5.000K
YoY Change -122.5% -108.06%
Pretax Income -$22.26M -$50.49M
YoY Change -59.39% 20.78%
Income Tax
% Of Pretax Income
Net Earnings -$22.26M -$50.49M
YoY Change -59.39% 20.77%
Net Earnings / Revenue -5919.15% -14805.28%
Basic Earnings Per Share -$1.72
Diluted Earnings Per Share -$0.76 -$1.72
COMMON SHARES
Basic Shares Outstanding 29.27M 29.27M
Diluted Shares Outstanding 29.27M

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $65.22M $90.00M
YoY Change -66.33% -61.26%
Cash & Equivalents $65.22M $89.96M
Short-Term Investments
Other Short-Term Assets $2.078M $2.171M
YoY Change -45.93% -10.66%
Inventory $1.991M $2.018M
Prepaid Expenses
Receivables $71.00K $700.0K
Other Receivables $0.00 $0.00
Total Short-Term Assets $72.14M $98.74M
YoY Change -64.44% -59.14%
LONG-TERM ASSETS
Property, Plant & Equipment $784.0K $862.0K
YoY Change -27.68% -27.38%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $87.00K $87.00K
YoY Change -90.59% -90.59%
Total Long-Term Assets $1.559M $1.711M
YoY Change -47.77% -45.8%
TOTAL ASSETS
Total Short-Term Assets $72.14M $98.74M
Total Long-Term Assets $1.559M $1.711M
Total Assets $73.70M $100.4M
YoY Change -64.2% -58.97%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $13.65M $10.67M
YoY Change 33.5% 81.69%
Accrued Expenses $12.42M $26.61M
YoY Change -33.45% 90.77%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $27.27M $39.41M
YoY Change -17.12% 68.57%
LONG-TERM LIABILITIES
Long-Term Debt $100.6M $99.09M
YoY Change 8.11% 8.07%
Other Long-Term Liabilities $2.345M $2.600M
YoY Change -25.06% -5.76%
Total Long-Term Liabilities $100.6M $99.09M
YoY Change 8.11% 8.07%
TOTAL LIABILITIES
Total Short-Term Liabilities $27.27M $39.41M
Total Long-Term Liabilities $100.6M $99.09M
Total Liabilities $130.2M $141.1M
YoY Change 0.88% 19.71%
SHAREHOLDERS EQUITY
Retained Earnings -$590.6M -$568.3M
YoY Change 43.51% 59.32%
Common Stock $30.00K $29.00K
YoY Change 7.14% 3.57%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$56.51M -$40.61M
YoY Change
Total Liabilities & Shareholders Equity $73.70M $100.4M
YoY Change -64.2% -58.97%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$22.26M -$50.49M
YoY Change -59.39% 20.77%
Depreciation, Depletion And Amortization $78.00K $79.00K
YoY Change -3.7% -7.06%
Cash From Operating Activities -$26.87M -$37.58M
YoY Change -30.47% 20.5%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.122M 0.000
YoY Change 4144.0% -100.0%
NET CHANGE
Cash From Operating Activities -26.87M -37.58M
Cash From Investing Activities 0.000 0.000
Cash From Financing Activities 2.122M 0.000
Net Change In Cash -24.74M -37.58M
YoY Change -35.88% 3202.28%
FREE CASH FLOW
Cash From Operating Activities -$26.87M -$37.58M
Capital Expenditures $0.00 $0.00
Free Cash Flow -$26.87M -$37.58M
YoY Change -30.47% 20.5%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
62000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
286000
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
dei Entity Central Index Key
EntityCentralIndexKey
0001720893
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
29273000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
28147000
CY2023Q3 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38410
dei Entity Registrant Name
EntityRegistrantName
BioXcel Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-1386754
dei Entity Address Address Line1
EntityAddressAddressLine1
555 Long Wharf Drive
dei Entity Address City Or Town
EntityAddressCityOrTown
New Haven
dei Entity Address State Or Province
EntityAddressStateOrProvince
CT
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
06511
dei City Area Code
CityAreaCode
475
dei Local Phone Number
LocalPhoneNumber
238-6837
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
BTAI
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
29272671
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
89961000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
193725000
CY2023Q3 us-gaap Receivables Net Current
ReceivablesNetCurrent
735000
CY2022Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
248000
CY2023Q3 us-gaap Inventory Net
InventoryNet
2018000
CY2022Q4 us-gaap Inventory Net
InventoryNet
1985000
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3853000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3067000
CY2023Q3 us-gaap Other Assets Current
OtherAssetsCurrent
2171000
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
3843000
CY2023Q3 us-gaap Assets Current
AssetsCurrent
98738000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
202868000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
862000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1084000
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
762000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
976000
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
87000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
925000
CY2023Q3 us-gaap Assets
Assets
100449000
CY2022Q4 us-gaap Assets
Assets
205853000
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
10669000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
10228000
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
26610000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
18669000
CY2023Q3 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
730000
CY2022Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
422000
CY2023Q3 us-gaap Interest Payable Current
InterestPayableCurrent
567000
CY2022Q4 us-gaap Interest Payable Current
InterestPayableCurrent
3175000
CY2023Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
832000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
404000
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
39408000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
32898000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
529000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
786000
CY2023Q3 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
2027000
CY2022Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
2343000
CY2023Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
99093000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
93051000
CY2023Q3 us-gaap Liabilities
Liabilities
141057000
CY2022Q4 us-gaap Liabilities
Liabilities
129078000
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
29273000
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
28147000
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
29000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
28000
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
527705000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
488292000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-568342000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-411545000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-40608000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
76775000
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
100449000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
205853000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
341000
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
137000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1004000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
137000
CY2023Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
512000
CY2022Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
11000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
546000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
11000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19619000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
22062000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
74392000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
58780000
CY2023Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
24344000
CY2022Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
17054000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
73810000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
48097000
CY2023Q3 us-gaap Restructuring Charges
RestructuringCharges
4163000
us-gaap Restructuring Charges
RestructuringCharges
4163000
CY2023Q3 us-gaap Costs And Expenses
CostsAndExpenses
48638000
CY2022Q3 us-gaap Costs And Expenses
CostsAndExpenses
39127000
us-gaap Costs And Expenses
CostsAndExpenses
152911000
us-gaap Costs And Expenses
CostsAndExpenses
106888000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-48297000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-38990000
us-gaap Operating Income Loss
OperatingIncomeLoss
-151907000
us-gaap Operating Income Loss
OperatingIncomeLoss
-106751000
CY2023Q3 us-gaap Interest Expense
InterestExpense
3252000
CY2022Q3 us-gaap Interest Expense
InterestExpense
3700000
us-gaap Interest Expense
InterestExpense
9879000
us-gaap Interest Expense
InterestExpense
5293000
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
1068000
CY2022Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
823000
us-gaap Investment Income Interest
InvestmentIncomeInterest
4703000
us-gaap Investment Income Interest
InvestmentIncomeInterest
1042000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-5000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
53000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-50486000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-41805000
us-gaap Net Income Loss
NetIncomeLoss
-156797000
us-gaap Net Income Loss
NetIncomeLoss
-110949000
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.72
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.49
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-5.40
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.96
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29268000
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
28022000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29026000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
27997000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
221667000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3825000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-31472000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
194020000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4482000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
3245000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
185000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-37672000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
164260000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4483000
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
48000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-41805000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
126986000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
76775000
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
23918000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4877000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
258000
CY2023Q1 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
-27000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-52796000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
53005000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6124000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
250000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-53515000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
5864000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4014000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-50486000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-40608000
us-gaap Profit Loss
ProfitLoss
-156797000
us-gaap Profit Loss
ProfitLoss
-110949000
us-gaap Depreciation
Depreciation
240000
us-gaap Depreciation
Depreciation
246000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
1066000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
538000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
316000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
63000
us-gaap Share Based Compensation
ShareBasedCompensation
15015000
us-gaap Share Based Compensation
ShareBasedCompensation
12790000
us-gaap Paid In Kind Interest
PaidInKindInterest
1215000
us-gaap Paid In Kind Interest
PaidInKindInterest
403000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-2000
btai Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
-214000
btai Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
-202000
us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
487000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
33000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1408000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1724000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
4934000
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
9098000
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
3795000
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
1153000
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
2896000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-237000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-218000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-128143000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-96702000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
20000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
139000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-20000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-139000
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
98600000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
2646000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
24657000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
739000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
27000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
508000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
233000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
24399000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
96187000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-103764000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-654000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
193725000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
232968000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
89961000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
232314000
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
3245000
us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note 1. Nature of the Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">BioXcel Therapeutics, Inc. (“BTI” or the “Company”) is a biopharmaceutical company utilizing artificial intelligence (“AI”) approaches to develop transformative medicines in neuroscience and immuno-oncology. The Company is focused on utilizing cutting-edge technology and innovative research to develop high-value therapeutics aimed at transforming patients’ lives. BTI employs unique AI platforms designed to reduce therapeutic development costs and potentially accelerate timelines. The Company’s approach leverages existing approved drugs and/or clinically evaluated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. BTI management believes this differentiated approach has the potential to reduce the expense and time associated with drug development in diseases with substantial unmet medical needs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As used in these condensed consolidated financial statements, unless otherwise specified or the context otherwise requires, the term “BioXcel LLC” refers to the Company’s former parent and current significant stockholder and its predecessor, BioXcel Corporation. “OnkosXcel” refers to BTI’s wholly owned subsidiary for its advanced immuno-oncology assets, OnkosXcel Therapeutics, LLC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On April 6, 2022, BTI announced that the U.S. FDA approved IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> (dexmedetomidine or “Dex”) sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> is approved to be self-administrated by patients under the supervision of a healthcare provider. On July 6, 2022, BTI announced that IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> was commercially available in doses of 120 and 180 micrograms through the Company’s third-party logistics provider and was available for order through wholesalers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company’s most advanced development program is BXCL501. In indications other than those approved by the FDA as IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup>, BXCL501 is an investigational proprietary, orally dissolving film formulation of Dex for the treatment of agitation associated with psychiatric and neurological disorders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company’s advanced immuno-oncology asset, BXCL701, is an investigational, orally administered systemic innate immune activator for the treatment of a rare form of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">BTI was incorporated under the laws of the State of Delaware on March 29, 2017. The Company’s principal office is in New Haven, Connecticut.</p>
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
89961000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-568342000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-50486000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-41805000
us-gaap Net Income Loss
NetIncomeLoss
-156797000
us-gaap Net Income Loss
NetIncomeLoss
-110949000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-128143000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-96702000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 18pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:normal;font-weight:normal;">The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect amounts reported in the condensed consolidated financial statements and notes thereto. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates.</span></p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 18pt;">Concentrations of Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">The Company sells IGALMI</span><sup style="font-size:7.5pt;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">TM</sup><span style="font-weight:normal;"> through a drop-ship program under which orders from hospitals and similar health care institutions are processed through wholesalers, but shipments of the product are sent directly to the individual hospitals and similar health care institutions. BTI also contracts directly with certain hospitals, and intermediaries such as group purchasing organizations (“GPOs”). All trade accounts receivables are due from the distributor that fulfills orders on behalf of the Company.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">​</span></p>
CY2023Q3 us-gaap Deferred Offering Costs
DeferredOfferingCosts
2570000
CY2023Q3 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
495000
us-gaap Revenue Recognition Accounting Policy Gross And Net Revenue Disclosure
RevenueRecognitionAccountingPolicyGrossAndNetRevenueDisclosure
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 18pt;"><b style="font-weight:bold;">Revenue Recognition</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company’s revenues consist of product sales of IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">BTI recognizes revenue when its customers obtain control of promised goods or services, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services. To determine revenue recognition, BTI management performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price, including variable consideration, if any; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. Arrangements that include rights to additional goods or services that are exercisable at a customer’s discretion are generally considered options. The Company assesses if these options provide a material right to the customer and if so, they are considered performance obligations. The exercise of a material right may be accounted for as a contract modification or as a continuation of the contract for accounting purposes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company assesses whether the goods or services promised within each contract are distinct to identify those that are performance obligations. This assessment involves subjective determinations and requires management to make judgments about the individual promised goods or services and whether such goods and services are separable from the other aspects of the contractual relationship. Promised goods and services are considered distinct provided that: (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer and (ii) the Company’s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company allocates the transaction price (the amount of consideration it expects to be entitled to from a customer in exchange for the promised goods or services) to each performance obligation and recognizes the associated revenue when (or as) each performance obligation is satisfied. The Company’s estimate of the transaction price for each contract includes all variable consideration to which the Company expects to be entitled.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">BTI distributes IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> in the U.S. through arrangements with a distributor, wholesalers, and GPOs. The distributor and wholesalers help process and fulfill orders from hospitals on the Company’s behalf. The Company believes the hospitals are its customers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company recognizes product revenues, net of consideration payable to customers, as well as variable consideration related to certain allowances and accruals that are determined using either the expected value or most likely amount method, depending on the type of the variable consideration, in its condensed consolidated financial statements at the point in time when control transfers to the customer, which is typically when the product has been delivered to the customer’s location. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. The Company’s only performance obligation identified for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> is to deliver the quantity of product ordered to the location specified by the customer’s order. The Company records shipping and handling costs associated with delivery of product to its customers within Selling, general and administrative expenses on its Condensed Consolidated Statements of Operations. Under the Company’s current product sales arrangements, BTI does not have contract assets (unbilled receivables), as it generally invoices its customer at the time of revenue recognition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">BTI sells IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> at wholesale acquisition cost and calculates product revenue net of variable consideration and consideration payable to third parties associated with distribution of product. The Company records reserves, based on contractual terms, for the following components of consideration related to product sold during the reporting period. Calculating these amounts involves estimates and judgments, and the Company reviews these estimates quarterly and records any material adjustments in the period they are identified, which affects net product revenue and earnings in the period such variances occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 18pt;"><span style="font-style:italic;font-weight:bold;">Trade Discounts and Allowances</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company provides the distributor and wholesalers with discounts for prompt payment and pays fees to the distributor, wholesalers and GPOs related to distribution of the product. BTI expects the relevant third parties to earn these discounts and fees, and therefore it deducts such amounts from gross product revenue and accounts receivable at the time it recognizes the related revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 18pt;"><span style="font-style:italic;font-weight:bold;">Government Rebates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> is eligible for purchase by, or qualifies for reimbursement from, Medicaid and other U.S. government programs that are eligible for rebates on the price they pay for the product. To determine the appropriate amount to reserve for these rebates, BTI applies the applicable government discount to these sales, and estimates the portion of total rebates that it anticipates will be claimed. The Company deducts certain government rebates from gross product </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">revenue and accounts receivable at the time it recognizes the related revenue; other government rebates are recognized as an accrued liability at the time BTI recognizes the related revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 18pt;"><span style="font-style:italic;font-weight:bold;">Chargebacks</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">BTI provides product discounts to hospitals associated with certain GPOs. The Company estimates the chargebacks that it expects to be obligated to provide based upon the terms of the applicable arrangements. BTI deducts such amounts from gross product revenue and accounts receivable at the time it recognizes the related revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 18pt;"><span style="font-style:italic;font-weight:bold;">Product Returns</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company provides contractual return rights to its customers including the right to return product within six months of product expiration and up to twelve months after product expiration, as well as for incorrect shipments, and damaged or defective product, which the Company expects to be rare. Management expects product returns to be minimal, thus BTI recognizes a nominal allowance for product returns at the time of each sale. In the future, if any of these factors and/or the history of product returns changes, the Company will adjust the allowance for product returns.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">BTI classifies all fees paid to the distributor, other than those discussed above and those related to warehouse operations, as Selling, general and administrative expenses on its Condensed Consolidated Statements of Operations. Fees paid to the distributor for warehouse operations are classified as Cost of goods sold on BTI’s Condensed Consolidated Statements of Operations.</p>
CY2022Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
0
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6370000
CY2023Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
8530000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2738000
CY2023Q3 us-gaap Taxes Payable Current
TaxesPayableCurrent
133000
CY2022Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
82000
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
756000
CY2023Q3 btai Restructuring And Related Cost Expected Number Of Positions Eliminated Percent
RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPercent
0.60
CY2023Q3 us-gaap Restructuring Charges
RestructuringCharges
4163000
CY2023Q3 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
3914000
CY2023Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
682000
CY2022Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
682000
CY2023Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
605000
CY2022Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
708000
CY2023Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
731000
CY2022Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
595000
CY2023Q3 us-gaap Inventory Net
InventoryNet
2018000
CY2022Q4 us-gaap Inventory Net
InventoryNet
1985000
CY2023Q3 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
495000
CY2023Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1977000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1969000
CY2023Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1115000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
885000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
862000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1084000
CY2023Q3 us-gaap Depreciation
Depreciation
79000
CY2022Q3 us-gaap Depreciation
Depreciation
85000
us-gaap Depreciation
Depreciation
240000
us-gaap Depreciation
Depreciation
246000
CY2023Q3 btai Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
9278000
CY2022Q4 btai Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
8659000
CY2023Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3999000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
820000
CY2023Q3 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
3914000
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
26610000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
18669000
CY2023Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
106413000
CY2022Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
101437000
CY2023Q3 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
7320000
CY2022Q4 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
8386000
CY2023Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
99093000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
93051000
CY2023Q3 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
26000
CY2023Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
741000
CY2023Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
1634000
CY2023Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
5633000
CY2023Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
93907000
CY2023Q3 btai Long Term Debt Maturities Repayments Of Principal After Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFour
5022000
CY2022Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
114000
us-gaap Operating Lease Expense
OperatingLeaseExpense
294000
us-gaap Operating Lease Expense
OperatingLeaseExpense
318000
CY2023Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
2875000
CY2022Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
3483000
us-gaap Interest Expense Debt
InterestExpenseDebt
8813000
us-gaap Interest Expense Debt
InterestExpenseDebt
4755000
CY2023Q3 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
377000
CY2022Q3 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
217000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
1066000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
538000
CY2023Q3 us-gaap Interest Expense
InterestExpense
3252000
CY2022Q3 us-gaap Interest Expense
InterestExpense
3700000
us-gaap Interest Expense
InterestExpense
9879000
us-gaap Interest Expense
InterestExpense
5293000
us-gaap Net Income Loss
NetIncomeLoss
-110949000
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
29268000
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
28022000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
29026000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4014000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4483000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
15015000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12790000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4014000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4483000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
15015000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12790000
us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
btai Lessee Operating Lease Number Of Renewal
LesseeOperatingLeaseNumberOfRenewal
1
CY2023Q3 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
93000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
381000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
391000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
65000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
930000
CY2023Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
62000
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
868000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
339000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
529000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
339000
CY2023Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
98000
CY2022Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
2343000
us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
-316000
CY2023Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
2027000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-50486000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-41805000
us-gaap Net Income Loss
NetIncomeLoss
-156797000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
27997000
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.72
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.49
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-5.40
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.96
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
5688000
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
5688000
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
4986000
CY2022Q2 us-gaap Significant Supply Commitment Remaining Minimum Amount Committed
SignificantSupplyCommitmentRemainingMinimumAmountCommitted
10000000
CY2022Q2 btai Agreement Commitment Period
AgreementCommitmentPeriod
P3Y

Files In Submission

Name View Source Status
btai-20230930_pre.xml Edgar Link unprocessable
btai-20230930_lab.xml Edgar Link unprocessable
0001558370-23-018917-index-headers.html Edgar Link pending
0001558370-23-018917-index.html Edgar Link pending
0001558370-23-018917.txt Edgar Link pending
0001558370-23-018917-xbrl.zip Edgar Link pending
btai-20230930.xsd Edgar Link pending
btai-20230930x10q.htm Edgar Link pending
btai-20230930x10q006.jpg Edgar Link pending
btai-20230930xex10d2.htm Edgar Link pending
btai-20230930xex31d1.htm Edgar Link pending
btai-20230930xex31d2.htm Edgar Link pending
btai-20230930xex32d1.htm Edgar Link pending
btai-20230930xex32d2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
btai-20230930_def.xml Edgar Link unprocessable
btai-20230930_cal.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
btai-20230930x10q_htm.xml Edgar Link completed
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending